Phenominer Database Results (101 results)

 

Table "column sort" updates the order of the bars in the chart.
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Record ID Study ID
F344/NHsd percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 10 20.0 % in vivo visual assessment 3024000.0 0 70148 1299
DA.F344-(D10Rat204-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 9 100.0 % in vivo visual assessment 3024000.0 0 70154 1299
E3/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) (for 56 days) Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4 joint integrity trait both 0 days 25 0.0 % in vivo visual assessment 4838400.0 0 69592 1160
DA.PVG-(D4Rat141-D4Mgh11) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 30 10.0 % in vivo visual assessment 0.0 0 70191 1301
DA/Bkl percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 77 days-105 days 10 50.0 % in vivo visual assessment 0.0 0 69551 1158
DA/Bkl percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 77 days-105 days 12 83.3 % in vivo visual assessment 0.0 0 69552 1158
BN/SsN percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 joint integrity trait both 66 days-126 days 13 0.0 % in vivo visual assessment 0.0 immunized 10 days variable 69961 850
E3 percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 10 0.0 % in vivo visual assessment 1.296E7 0 70130 1282
LEW.1AV1 percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 9 11.0 % in vivo visual assessment 0.0 0 69629 1161
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 18 33.0 % in vivo visual assessment 0.0 0 69717 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 16 69.0 % in vivo visual assessment 0.0 0 69718 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69724 1162
E3/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16. joint integrity trait both 56 days-84 days 10 0.0 % in vivo visual assessment 2419200.0 0 69839 1164
DA/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 17 100.0 % in vivo visual assessment 0.0 0 69716 1162
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male 0 days 24 100.0 % in vivo visual assessment 0.0 0 84465 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 15 93.0 % in vivo visual assessment 0.0 0 84469 1301
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait male 56 days-84 days 14 86.0 % in vivo visual assessment 0.0 0 69813 1163
DA/Bkl percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 14 100.0 % in vivo visual assessment 3024000.0 0 70147 1299
PVG.1AV1/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 29 0.0 % in vivo visual assessment 0.0 0 70190 1301
PVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 16 68.8 % in vivo visual assessment 0.0 0 84872 1301
DA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 9 22.0 % in vivo visual assessment 0.0 0 84876 1301
DA/Bkl percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 15 100.0 % in vivo visual assessment 3024000.0 0 70146 1299
F344/NHsd percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 10 30.0 % in vivo visual assessment 3024000.0 0 70149 1299
DA.PVG.1AV1-(D4Mgh17-D4Rat56) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 100.0 % in vivo visual assessment 0.0 0 70199 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 37 5.0 % in vivo visual assessment 0.0 0 70201 1301
LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 13 77.0 % in vivo visual assessment 0.0 0 69644 1161
LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 26 69.0 % in vivo visual assessment 0.0 0 69646 1161
E3/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 23 9.0 % in vivo visual assessment 0.0 0 69664 1159
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 90.0 % in vivo visual assessment 0.0 0 69725 1162
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait female 56 days-84 days 8 100.0 % in vivo visual assessment 0.0 0 69814 1163
DA/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16. joint integrity trait both 56 days-84 days 104 100.0 % in vivo visual assessment 2419200.0 0 69838 1164
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 33.0 % in vivo visual assessment 0.0 0 69710 1162
DA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 10 100.0 % in vivo visual assessment 0.0 0 84879 1301
DA.LEW.1AV1-(D4Mgh17-D4Mgh21)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 14 0.0 % in vivo visual assessment 0.0 0 84873 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 45.0 % in vivo visual assessment 0.0 0 84878 1301
DA/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 17 100.0 % in vivo visual assessment 0.0 0 69663 1159
E3 percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait male 56 days-84 days 5 0.0 % in vivo visual assessment 0.0 0 69815 1163
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 11 73.0 % in vivo visual assessment 0.0 0 69705 1162
DXE3/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) (for 110 days) Nordquist N, et al., J Autoimmun 2000 Dec;15(4):425-32. joint integrity trait both 0 days 29 3.0 % in vivo visual assessment 9504000.0 0 70142 1298
DA.PVG.1AV1-(D4Rat155-Spr) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 25.0 % in vivo visual assessment 0.0 0 70197 1301
DA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 55.0 % in vivo visual assessment 0.0 0 84889 1301
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 0.0 % in vivo visual assessment 0.0 0 84874 1301
DA/Bkl percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 joint integrity trait both 66 days-126 days 105 100.0 % in vivo visual assessment 0.0 immunized 10 days variable 69959 850
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 100.0 % in vivo visual assessment 0.0 0 69625 1161
LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 28 50.0 % in vivo visual assessment 0.0 0 69647 1161
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 9 100.0 % in vivo visual assessment 0.0 0 69720 1162
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69723 1162
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female 0 days 24 91.7 % in vivo visual assessment 0.0 0 84466 1301
DA/Bkl percentage of study population developing experimental arthritis during a period of time 0.9% sodium chloride solution (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 77 days-105 days 10 0.0 % in vivo visual assessment 0.0 0 97070 1158
LEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 13 15.4 % in vivo visual assessment 0.0 0 70193 1301
DA/Bkl percentage of study population developing experimental arthritis during a period of time 0.9% sodium chloride solution (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 77 days-105 days 12 0.0 % in vivo visual assessment 0.0 0 97071 1158
DA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 8 100.0 % in vivo visual assessment 0.0 0 84884 1301
LEW.1AV1/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 0.0 % in vivo visual assessment 0.0 0 70189 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 5 100.0 % in vivo visual assessment 0.0 0 70192 1301
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 8 100.0 % in vivo visual assessment 0.0 0 69624 1161
LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 13 85.0 % in vivo visual assessment 0.0 0 69627 1161
LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 17 29.0 % in vivo visual assessment 0.0 0 69642 1161
LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 33.0 % in vivo visual assessment 0.0 0 69643 1161
DXE2/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 24 33.0 % in vivo visual assessment 0.0 0 69666 1159
DA.PVG.1AV1-(D4Mgh17-D4Rat56) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 11 100.0 % in vivo visual assessment 0.0 0 69713 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 9 100.0 % in vivo visual assessment 0.0 0 69714 1162
DA.PVG.1AV1-(D4Rat155-Spr) percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 24 100.0 % in vivo visual assessment 0.0 0 69719 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 16 88.0 % in vivo visual assessment 0.0 0 69706 1162
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 0.0 % in vivo visual assessment 0.0 0 69707 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 12 100.0 % in vivo visual assessment 0.0 0 69709 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 71.0 % in vivo visual assessment 0.0 0 69711 1162
DA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 9 100.0 % in vivo visual assessment 0.0 0 84875 1301
DA.PVG.1AV1-(D4Got126-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 43.0 % in vivo visual assessment 0.0 0 84881 1301
DA.PVG.1AV1-(D4Got126-D4Got136) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 14 64.0 % in vivo visual assessment 0.0 0 84886 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 6 100.0 % in vivo visual assessment 0.0 0 84470 1301
DA/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 10 100.0 % in vivo visual assessment 1.296E7 0 70128 1282
DXE1/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 20 10.0 % in vivo visual assessment 0.0 0 69681 1159
DA.F344-(D10Arb20-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 10 100.0 % in vivo visual assessment 3024000.0 0 70152 1299
DA.F344-(D10Rat204-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 10 100.0 % in vivo visual assessment 3024000.0 0 70155 1299
LEW/SsNHsd percentage of study population developing experimental arthritis during a period of time 0.9% sodium chloride solution (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait not specified 77 days-105 days 6 0.0 % in vivo visual assessment 0.0 0 97069 1158
DA.PVG.1AV1-(D4Rat62-D4Got136)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 75.0 % in vivo visual assessment 0.0 0 84882 1301
DA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 18 89.0 % in vivo visual assessment 0.0 0 84892 1301
DA.F344-(D10Arb20-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 10 100.0 % in vivo visual assessment 3024000.0 0 70153 1299
DA/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) (for 56 days) Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4 joint integrity trait both 0 days 30 93.0 % in vivo visual assessment 4838400.0 0 69591 1160
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 11 100.0 % in vivo visual assessment 1.296E7 0 70129 1282
LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 15 73.0 % in vivo visual assessment 0.0 0 69626 1161
LEW.1AV1 percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 14 14.0 % in vivo visual assessment 0.0 0 69628 1161
LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 17 71.0 % in vivo visual assessment 0.0 0 69645 1161
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 10 100.0 % in vivo visual assessment 0.0 0 69661 1159
LEW.1N percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 11 64.0 % in vivo visual assessment 0.0 0 69662 1159
DXE3/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 20 10.0 % in vivo visual assessment 0.0 0 69667 1159
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69721 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69722 1162
E3 percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait female 56 days-84 days 5 0.0 % in vivo visual assessment 0.0 0 69816 1163
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 100.0 % in vivo visual assessment 0.0 0 69703 1162
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 0.0 % in vivo visual assessment 0.0 0 69704 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 36.0 % in vivo visual assessment 0.0 0 69708 1162
DA.PVG.1AV1-(D4Rat155-Spr) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 100.0 % in vivo visual assessment 0.0 0 69712 1162
DA.PVG.1AV1-(D4Mgh17-D4Rat56) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 13 100.0 % in vivo visual assessment 0.0 0 69715 1162
DA.PVG.1AV1-(D4Rat203-D4Got130)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 100.0 % in vivo visual assessment 0.0 0 84877 1301
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 100.0 % in vivo visual assessment 0.0 0 84883 1301
LEW/Han percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 11 82.0 % in vivo visual assessment 0.0 0 69660 1159
DXE1/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 20 70.0 % in vivo visual assessment 0.0 0 69665 1159
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 27 96.3 % in vivo visual assessment 0.0 0 70188 1301
LEW/SsNHsd percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait not specified 77 days-105 days 6 0.0 % in vivo visual assessment 0.0 0 97068 1158
DA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 100.0 % in vivo visual assessment 0.0 0 84880 1301